SCIENTIFIC PROGRAM

Friday, June 24, 2022

8:30 AM  Introduction by Workshop Director A Mebazaa (Paris, FR)

8:45 AM  SESSION 1: HOW DOES THE MANAGEMENT OF CARDIOGENIC SHOCK LOOK IN THE FUTURE?
Co-Chairs: S Price (London, UK) & D Morrow (Boston, US)

Novelties in Cardiogenic Shock classification: J Jentzer (Rochester, US)
Escalation / de-escalation of therapies: N Kapur (Boston, US)
Ongoing trials: U Zeymer (Ludwigshafen, DE)
Urgent medical needs: N Aissaoui (Paris, FR)
Nurse’s perspective: C Rosner (Falls Church, US)
Patient’s perspective: R Monroe (Charlotte, US)
Regulators’ perspective: M Moscucci (FDA, USA)
NIH’s perspective: Y Rosenberg (NHLBI, USA)
Panel discussion

11:00 AM  Coffee Break

11:20 AM  SESSION 2: LONG TERM OUTCOMES AFTER ICU DISCHARGE
Co-Chairs: A Blet (Lyon, FR) & R Monroe (Charlotte, US)

Why post-ICU long-term outcomes matter?: E Gayat (Paris, FR)
Use of administrative data for in silico follow-up: R Pirracchio (San Francisco, US)
Use of telemedicine for long-term follow-up: M Cowie (London, UK)
Which long-term outcomes are relevant for future trials? M Harhay (Philadelphia, US)
Regulators’ perspective: FDA: N Stockbridge (FDA, US), EMA: M Kostubric (EMA, POL)
Panel discussion

1:30 PM  Lunch break

2:30 PM  SESSION 3: MORTALITY IS DEAD? THE IMPORTANCE OF ALTERNATIVE OUTCOMES IN CRITICAL CARE TRIALS
Co-Chairs: J Pöss (Leipzig, DE), S Collins (Nashville, US)

Free Day Outcomes - OFDs as an example: W Self (Nashville, US)
Defining patient recovery: S-M Brown (Salt Lake City, US)
PROs: C Hough (Portland, US)
Hierarchical outcomes: B Davison (Momentum Research, US)
Optimizing the Analytic Approach to non-Mortality Based Outcomes: R Lewis (Los Angeles, US)
Patient perspective: E Rubin (Northbrook, US)
Regulators’ perspective: FDA: N Stockbridge (FDA, US), EMA: M Kostubric (EMA, POL)
NIH perspective: J Fessel & S Dunsmore (NIH, US)
Industry perspective: S Sonntag (Virtonomy, DE)
Panel Discussion

5:30 PM  Adjourn & dinner in the French Embassy
Saturday, June 25, 2022

8:30 AM  **SESSION 4: ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)**
Co-Chairs: D Stanley (The Lancet, US) & C Barkauskas (Durham, US)

ACTIV-3/TICO Platform Trial: Design and Main Results: A Ginde (Aurora, US)
TESICO-VIP trial: C Barkauskas (Durham, US)
Update on global definition of ARDS: M Matthay (San Francisco, US)
ARDS trials funded by NHLBI: L Reineck (NHLBI, US)
RAGE: K Wick (San Francisco, US)
Sample size mis-estimation in ARDS trials: M Shankar-Hari (London, UK)
Patient perspective: E Rubin (Northbrook, US)
Panel Discussion

10:30 AM  Coffee Break

11:00 AM  **SESSION 5: LATE-BREAKING TRIALS**
Co-Chairs: S Spencer (The Lancet, UK), S Price (London, UK)

Vitamin C for Septic Shock – LOVIT trial Results: M Matthay (San Francisco, US)
SEISMIC: A Mebazaa (Paris, FR)
PANAMO: N Riedemann (InflaRx, DE)
Panel Discussion

12:00 PM  **SESSION 6: TRIALS HELPED DEFINING SEPTIC SHOCK**
Co-Chairs: N Nielsen (Albuquerque, US), I Piña (FDA, US)

News from ASTONISH - Opening the way to a registration trial?: B François (Limoges, FR)
Encourage program: P-F Laterre (Brussels, BE)
Revival trial: P Pickkers (Nijmegen, NL)
Post discharge outcome of Septic Shock: A Blet (Lyon, FR)
Are phenotypes exclusive to a type of shock?: S Soussi (Toronto, CA)
Promising results of Procizumab in a pre-clinical model of septic shock: A Herpain (Brussels, BE)
Industry perspective: A Bergmann (4TEEN4, Germany)
Industry perspective: M Salcedo (Inotrem, FR)
Industry perspective: E Galamidi (Enlivex, IL)
Regulators’ perspective: M Kostrubiec (EMA, Poland)
Panel discussion

2:00 PM  Adjourn & Lunch in the French Embassy

---

This sign indicates that the faculty member was not able to attend the Workshop in person but is connected remotely via video. Feel free to reach out to them on the virtual platform available. Overcome staff onsite can assist you in accessing it.